Niki BioSolutions: enters ATM equity offering for up to $1,396,000

What happened Niki BioSolutions reported that on Oct 9, 2026 it entered into an At the Market Offering Agreement with H.C. Wainwright & Co., LLC and Brookline Capital Markets, a division of Arcadia Securities, LLC to sell shares of its common stock in an at-the-market offering. The company filed a prospectus supplement and base prospectus on Oct 9, 2026 under its Form S-3 registration statement in connection with the offering.

Key details

• Maximum aggregate offering price: up to $1,396,000 of common stock.
• Placement fee: the company will pay Wainwright a placement fee equal to 3.0% of the gross sales price of shares sold by Wainwright as sales agent.
• Conflict of interest: the filing states that the company’s largest shareholder and a director, Dr. Kira Sheinerman, is a managing director of Wainwright, creating a conflict under FINRA Rule 5121(f)(5); Brookline agreed to act as the qualified independent underwriter for no additional compensation.
• Company obligations: the company has no obligation to sell any shares; either party may suspend or terminate the offering in accordance with the Sales Agreement; Wainwright is not obligated to purchase shares as principal unless separately agreed.

Why it may matter

• Item reported: Item 1.01 (entry into a material definitive agreement). The item covers the terms of the at-the-market sales agreement, including offering size, sales agent duties, compensation, conflicts of interest and related indemnities. This filing does not show why the insider traded or why the company acted.